Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
ConditionPostherpetic Neuralgia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
Eligibility criteria
Qualifiers
Ages more than 18 years;
Pain present for more than 3 months after healing of a herpes zoster skin rash;
Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
Failed to respond to or tolerate the effective dose of pregabalin monotherapy.
Disqualifiers
Obstructive sleep apnoea syndrome;
Those who receive interventional treatments;
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic or renal dysfunction;
Trial design
Treatments tested in this trial
- esketamine group
- control group
Treatment groups
150 Participants
are divided into 2 treatment groupsLocations
1Beijing Tiantan Hospital100070, BeijingBeijing Municipality, China
Sponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Xiaotangshan Hospital
Collaborator
The First Hospital of Fangshan District,Beijing
Collaborator
Beijing Ditan Hospital
Collaborator
Hengshui People's Hospital
Collaborator
Source ClinicalTrials.gov